Khondrion announces publication of results of integrated Phase 2b programme
15 Nov, 2024
On 7 November, biopharmaceutical company Khondrion announced the publication of results from their integrated Phase 2b clinical development programme which uses the drug sonlicromanol to target the underlying pathways of primary mitochondrial disease. The programme demonstrated improvements in several domains including the brain and muscles which are commonly affect by PMD. Khondrion’s CEO, Prof. Dr. Jan Smeitink, said, “To our knowledge, this is the first time a trial has shown clear reversal of the hallmark phenotypical symptoms in otherwise progressive mitochondrial disease.”